

In the Claims:

Claims 1, 2, 3, and 13 have been amended. Claims 44-47 have been added.

1. (Amended) A drug release system comprising:

a bulk polymer phase;

a polymeric drug-enriched phase within the bulk polymer phase, the polymeric drug-enriched phase being substantially or completely insoluble in the bulk polymer phase; and

a drug incorporated into the drug-enriched phase, the drug having preferential solubility for the polymeric drug-enriched phase than the bulk polymer phase wherein the bulk polymeric phase is substantially or completely devoid of the drug.

2. (Amended) The drug release system of claim 1 wherein the drug-enriched phase comprises sites within the bulk polymer phase that are not interconnecting.

3. (Amended) The drug release system of claim 1 wherein the drug-enriched phase comprises sites within the bulk phase that are intermittent in cross-section and continuous in a longitudinal direction.

13. (Amended) The drug release system of claim 1 wherein the drug enriched phase is conjugated to the bulk polymer phase via a urethane linkage.

44. (New) A drug release system for a stent, comprising:

a first polymer;

a second polymer combined with the first polymer, the second polymer being significantly or completely insoluble in the first polymer; and